Assessment and management of TIA 2013. 12. 06 Andre Douen MD, PhD, FRCPC, FAHA Director West GTA Regional Stroke Program, Chief, Division of Neurology, Trillium Health Partners Mississauga CMO, Innovate R&D www.educatehealth.ca Disclosures: Ad Board: BI, Sanofi- Aventis, Pfizer, BMS, Bayer Speaker: BI, BMS, Pfizer
88
Embed
Assessment and management of TIA 2013. 12. 06 Andre Douen MD, PhD, FRCPC, FAHA Director West GTA Regional Stroke Program, Chief, Division of Neurology,
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Assessment and management of TIA2013. 12. 06
Andre Douen MD, PhD, FRCPC, FAHADirector West GTA Regional Stroke Program,Chief, Division of Neurology,Trillium Health Partners MississaugaCMO, Innovate R&Dwww.educatehealth.ca
• PMH:o Smoking 1ppd x 30 yrso No HTN, No DM, No Cholesterol at her
last visit in Jan 2010
Douen
Case 1 Mrs W.S.• HPI
o Speaking with niece regarding a legal matter when..
o Slurred speech Loss of speecho Right facial droop, Right arm weak and
incoordinated
• EMS o Symptoms resolved with 15 mino Patient declines transfer to ERo Elects to wait overnight and call fam doc
in AM for a quick visit and head to office after to prepare for prosecuting a medico-legal case Douen
CaseExamination in office the next day:
BP = 160/90 ; HR 90 and regular. No neurological deficits, but with right carotid bruit
Current Meds: Losec, Tylenol prn for back pain
Next steps:– DDX ? [Is this a TIA, if not what could it be ?]– If TIA, what’s her risk of recurrent stroke ? – Is there a tool that can help assess this ? – What investigations is needed now ?– What should I do...panic ? [Will I get sued if I make
the wrong decision ? ]– Should I start Meds ?– Maybe the ER might be a safe bet ?
Stroke/TIA Mimics• Migraine (aura)• Vertigo • Syncope (vaso-vagal, cardiogenic, metabolic)• Seizure (simple, CPSz, grand mal with “Todd’s”)• Structural brain lesions (tumors, AVM, subdurals,
Next steps:– DDX ? [Is this a TIA, if not what could it be ?]– If TIA, what’s her risk of recurrent stroke ? – Is there a tool that can help assess this ? – What investigations are needed now ? How soon ?– What should I do...panic ? [Will I get sued if I make
the wrong decision ? ]– Should I start Meds ?– Maybe the ER might be a safe bet ?
What investigations would you consider for this patient (why, when)?
Albers GW, et al. Chest 2004; 126 (3 Suppl): 438S–512SMcGrath et al. Stroke 2012; 43: 2048-2054.
Boehringer Ingelheim (Canada) Ltd. cannot recommend the use of products outside the Canadian approved Product Monograph.The content of this slide may contain information not reviewed by Health Canada.
2. What priority would you give these investigations?
a) ECG > ECHO> Telemetry/Holter>Carotid Doppler>CT
b) CT>Telemetry/Holter>ECHO>Carotid Doppler> ECG
c) ECHO > Holter > CT>Carotid Doppler > ECG
d) CT> Carotid Doppler = ECG > Holter > ECHO
e) CT = ECG = Carotid Doppler > Holter > ECHO
2. What priority would you give these investigations?
a) ECG > ECHO> Telemetry/Holter>Carotid Doppler>CT
b) CT>Telemetry/Holter>ECHO>Carotid Doppler> ECG
c) ECHO > Holter > CT>Carotid Doppler > ECG
d) CT> Carotid Doppler = ECG > Holter > ECHO
e) CT = ECG = Carotid Doppler > Holter > ECHO
Cardioemboli
• AF: High incidence of paroxysmal AF in acute stroke 13.5% detection of new onset AF using a
combination of serial ECG daily x 3 days plus Holter Overall ~20 % of acute stroke patient with AF.
(Douen et al, Stroke 2008)
• Up to 3 million people worldwide suffer strokes related to AF each year1-3
1. Atlas of Heart Disease and Stroke, World Health Organization, September 2004. Viewed at http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 2. 1991:22(8);983-8
3. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996;27:1760-4
Prolonged Ambulatory Cardiac Monitoring Improves the Detection and Treatment of Atrial Fibrillation in Patients with Cryptogenic Stroke: Primary Results from the EMBRACE Multicenter Randomized Trial Gladstone DJ, International Stroke Conference, Honolulu, 2013
n=572 (age 73±9yrs;); recent ischemic cryptogenic stroke/TIA, no known AF; 16 stroke centers
Randomized to wear either an event-triggered cardiac monitor up to 30 days or a repeat 24 h Holter
New AF detected among 16% of 30-day monitoring group, vs. 3% in the Holter group (p<0.001)
Presented by: Gladstone DJ, International Stroke Conference, Honolulu, HI
30-day Holter0%
2%
4%
6%
8%
10%
12%
14%
16%
18%16%
3%
New AF
P<0.001
Case
Next steps:– DDX ? [Is this a TIA, if not what could it be ?]– If TIA, what’s her risk of recurrent stroke ? – Is there a tool that can help assess this ? – What investigations are needed now ? How soon ?– What should I do...panic ? [Will I get sued if I make
the wrong decision ? ]– Should I start Meds ?– Maybe the ER might be a safe bet ?
3. Which of the following statements about the management of patients with TIA or minor stroke are correct:a. If possible work-up should be completed within 2-3
days
b. Early treatment and intervention could reduce stroke recurrence by 80%
c. Early management through a stroke clinic is likely superior to routine out patient management.
d. For those with ipsilateral severe stenosis revascularization is recommended within 2 weeks
e. All of the above
3. Which of the following statements about the management of patients with TIA or minor stroke are correct:a. If possible work-up should be completed within 2-3
days
b. Early treatment and intervention could reduce stroke recurrence by 80%
c. Early management through a stroke clinic is likely superior to routine out patient management.
d. For those with ipsilateral severe stenosis revascularization is recommended within 2 weeks
e. All of the above
EXPRESSUrgent treatment of TIA and minor stroke
Outcome Phase 1 Phase 2
Time to clinic visit - 3 days ( 2 -5) 1 day (0-3)
Time to prescription- *20 days (8 -53) 1 day (0-3)
90 day risk of stroke- ~10.3% 2.1%**
*No prescriptions given. Patients advised to see family MD
** 80% reduction in risk of recurrent stroke
Timeliness of Care In Patients with TIA The OXVASC Study
Neurology 2005;65:371-5.
Neurology 2005;65:371-5.c
The Consequences of Delaying Access to CareThe OXVASC Study
Neurology 2005;65:371-5.
Stroke Patients
Neurology 2005;65:371-5.c
30.2
14.817.6
3.3
11.4
4
8.9
-2.9
-10
0
10
20
30
40 70-99% Stenosis
50-69% Stenosis
0-2 4-122-4 >12
Time From Event to Randomization (weeks)
5 Year ARRIn Stroke
(%)
Timing of Surgical InterventionThe NASCET and ECST Studies
Lancet 2004;363:915-24.
CaseNext steps :
– DDX ? [Is this a TIA, if not what could it be ?]
– If TIA, what’s her risk of recurrent stroke ?
– Is there a tool that can help assess this ?
– What investigations are needed now ? How soon ?
– What should I do...panic ? [Will I get sued if I make the wrong decision ? ]
– Should I start Meds ?
– Maybe the ER might be a safe bet ?
Stroke / TIA
Medical
Risk factor management
Interventional
Revascularization
CEA vs Stent
Antiplatelet Anticoagulant
Antithrombotic
4. Following and ischemic stroke it is best to wait 3 - 4 days before initiating antiplatelet therapy because of increased risk of bleeding.a. True
b. False
4. Following and ischemic stroke it is best to wait 3 - 4 days before initiating antiplatelet therapy because of increased risk of bleeding.a. True
b. False
5. In an ASA naive patient which of the following Antitrhombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
a. ASA
b. ASA/ER Dipyridamole
c. Clopidogrel
d. Clopidogrel + ASA
e. Warfarin
f. Either b) or c)
g. Any of a) , b) or c)
5. In an ASA naive patient which of the following Antitrhombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
a. ASA
b. ASA/ER Dipyridamole
c. Clopidogrel
d. Clopidogrel + ASA
e. Warfarin
f. Either b) or c)
g. Any of a) , b) or c)
Prevention of Vascular Events in Stroke/TIA Patients with ASA Following First Stroke
ASA vs. Placebo: Efficacy by Dose*
ASA Dose Relative Risk of Vascular Events**
1,000 – 1,300 mg/d
300 mg/d
50 – 75 mg/d
Overall
0.8†
ASA better Placebo better
* A meta-analysis of 10 controlled trials comparing acetylsalicylic acid (ASA) with placebo. ** Vascular events comprise stroke, MI, or vascular death.† Signifies a 20% relative risk reduction
Adapted from Albers GW et al. Neurology. 1999; 53(suppl 4): S25-S38.
6. For patients already on ASA which of the following Antitrhombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
a. ASA
b. ASA/ER Dipyridamole
c. Clopidogrel
d. Clopidogrel + ASA
e. Warfarin
f. Either b) or c)
g. Any of a) , b) or c)
6. For patients already on ASA which of the following Antitrhombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
7. For patients already on Clopidogrel which of the following Antithrombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
a. ASA/ER Dipyridamole
b. Clopidogrel
c. Clopidogrel + ASA
d. Warfarin
e. Either a) or b)
7. For patients already on Clopidogrel which of the following Antithrombotic agents is recommended for secondary prevention of Non-Cardioembolic stroke
a. ASA/ER Dipyridamole
b. Clopidogrel
c. Clopidogrel + ASA
d. Warfarin
e. Either a) or b)
Case
CT brain: Nil acute
ECG: AF with HR of 95
Is a Doppler still required ??
Meds: …. ???
What is incidence of AF in acute stroke ??
Case
CT brain: Nil acute
ECG: AF with HR of 95
Is a Doppler still required ?? YES
Meds: …. ???
What is incidence of AF in acute stroke ??
Stroke / TIA
Medical
Risk factor management
Interventional
Revascularization
CEA vs Stent
Antiplatelet Anticoagulant
Antithrombotic
Cardioemboli
• AF: o High incidence of paroxysmal AF in acute strokeo 13.5% detection of new onset AF using a
combination of serial ECG daily x 3 days plus Holtero Overall ~20 % of acute stroke patient with AF
(Douen et al, Stroke 2008)
• Up to 3 million people worldwide suffer strokes related to AF each year1-3
1. Atlas of Heart Disease and Stroke, World Health Organization, September 2004. Viewed at http://www.who.int/cardiovascular_diseases/en/cvd_atlas_15_burden_stroke.pdf
2. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 2. 1991:22(8);983-8
3. Lin HJ, Wolf PA, Kelly-Hayes M, et al. Stroke severity in atrial fibrillation: the Framingham study. Stroke 1996;27:1760-4
Prolonged Ambulatory Cardiac Monitoring Improves the Detection and Treatment of Atrial Fibrillation in Patients with Cryptogenic Stroke: Primary Results from the EMBRACE Multicenter Randomized Trial Gladstone DJ, International Stroke Conference, Honolulu, 2013
n=572 (age 73±9yrs;); recent ischemic cryptogenic stroke/TIA, no known AF; 16 stroke centers
Randomized to wear either an event-triggered cardiac monitor up to 30 days or a repeat 24 h Holter
New AF detected among 16% of 30-day monitoring group, vs. 3% in the Holter group (p<0.001)
Presented by: Gladstone DJ, International Stroke Conference, Honolulu, HI
30-day Holter0%
2%
4%
6%
8%
10%
12%
14%
16%
18%16%
3%
New AF
P<0.001
AF increases the risk of stroke
• AF is associated with a pro-thrombotic stateo ~5- 17 fold increase in stroke risk
• Risk of stroke is the same in patients with chronic of PAF2,3
• There is a high 30-day mortality (~25%) following cardioembolic stroke4
• AF-related stroke has a 1-year mortality of ~50%5
1. Wolf PA, et al. Stroke 1991;22:983-988; 2. Rosamond W et al. Circulation. 2008;117:e25–146; 3.Hart RG, et al. J Am Coll Cardiol 2000;35:183-187; 4. Lin H-J, et al. Stroke 1996; 27:1760-1764; 5. Marini C, et al. Stroke 2005;36:1115-1119.
Stroke Severity in Patients with AF
Gladstone DJ et al. Stroke. 2009; 40:235-240
Effect of first ischemic stroke in patients with AF (n=597)%
of
pati
ents
Disabling(discharge mRS ≥ 2)
Fatal
60%
40%
0%
50%
30%
20%
10%
59.7%
20%
mRS=modified Rankin ScaleAF=atrial fibrillation
Ischemic Stroke Associated With AF is Typically More Severe Than Stroke due to Other Etiologies
% b
edri
dden p
ati
ents
on a
dm
issi
on (
mR
s* =
5)
(P < 0.0005)
40
30
20
10
0
50
41.2%
23.7%
With AF Without AF
Dulli DA, et al. Neuroepidemiology. 2003;22:118-123.
Odds ratio for bedridden state following stroke due to AF was 2.23 (95% CI, 1.87-2.59; P < 0.0005)
*mRS=modified Rankin ScaleAF=atrial fibrillation
Increased mortality after ischemic stroke in patients with AF persists for up to 8 years
•Population-based study of 3530 patients with ischaemic stroke•Marini C et al. Stroke 2005;36:1115–9
Patients with AF (n=869)
Patients without AF (n=2661)
Years after stroke
An
nu
al m
ort
alit
y ra
te (
%)
0
10
20
30
40
50
60 Mortality
1 2 3 4 5 6 7 8
AF associated with increased risk of recurrent stroke
Marini C et al. Stroke 2005;36:1115–9
Patients with AF
Patients without AF
Recurrent stroke after ischemic stroke
Months after first stroke
Cu
mu
lati
ve p
rob
abili
ty
of
recu
rren
ce (
%)
10
12
8
6
4
2
00 2 4 6 8 10
P=0.0398
Missed Opportunities for Stroke Prevention in AF:Registry of the Canadian Stroke Network 2003-2007
Gladstone Stroke 2009;40:235
No antithrombotics Dual antiplatelets Single antiplatelet Warfarin: therapeutic Warfarin: sub-therapeutic
Preadmission medications in patients with known AF admitted with acute
ischemic stroke (high-risk cohort, n=597)
Preadmission medications in patients with known AF and a previous ischemic
stroke/TIA admitted with acute ischemic stroke
(very high-risk cohort, n=323)
Need for greater efforts to prescribe and monitor appropriate antithrombotic therapy to prevent stroke in patients with AF
9. The patients who benefit the most from warfarin therapy are those with AF in the age group 65-75 and with no other medical issues. OAC (e.g. warfarin) is not beneficial for the elderly
True
False
9. The patients who benefit the most from warfarin therapy are those with AF in the age group 65-75 and with no other medical issues. OAC (e.g. warfarin) is not beneficial for the elderly
True
False
AF prevalence increases with age
1. Go AS, et al. JAMA 2001;285:2370-2375.Age
AF
pre
va
len
ce
(%)
General population
>60 years >80 years
9
8
7
6
5
4
3
2
1
0
10. Patients with AF who has spontaneous intracranial hemorrhage while using OAC should never be placed back on OAC
True
False
10. Patients with AF who have spontaneous intracranial hemorrhage while using OAC should never be placed back on OAC True False
Cause of bleed needs to be assessed: Elevated INR Concomitant use of antiplatelet agent Overdose of NOAC CrCl Drug abuse H/o trauma/fall HGB, plts etc Risk benefit ratio
CHADS 2
CHADS2 Score* Stroke rate
0 1.9 (1.2 -3.0)
1 2.8 (2.0-3.8)
2 4.0 (3.1-5.1)
3 5.9 (4.6-7.3)
4 8.5 (6.3 -11.1)
5 12.5 (8.2-17.5)
6 18.2 (10.5-17.4)
*Score 0: Patients can be administered aspirin*Score 1: Patients can be on aspirin and anticoagulant therapy*Score ≥2: Patients should be on anticoagulant therapy
• 1 point for Congestive Heart Failure
• 1 point for Hypertension
• 1 point for Age ≥ 75 years• 1 point for Diabetes Mellitus • 2 points for Prior Stroke or
TIA
CHA2DS2-VASc Score
• 1 point for Congestive Heart Failure/LV Dysfunction
• 1 point for Hypertension
• 2 points for Age ≥ 75 years
• 1 point for Diabetes Mellitus
• 2 points for Prior Stroke or TIA1 or TE2
• 1 point for Vascular Disease3
• 1 point for Age 65-74 years
• 1 point for Sex category (female gender)
CHA2DS2-VASc Score*
One year event rate (95% CI) of hospital admission and death due to thromboembolism† per 100 person
year
0 0.78 (0.78 – 1.04)
1 2.01 (1.70 – 2.36)
2 3.71 (3.36 – 4.09)
3 5.92 (5.53 – 6.34)
4 9.27 (8.71 – 9.86)
5 15.26 (14.35 – 16.24)
6 19.74 (18.21 – 21.41)
7 21.5 (18.75 – 24.64)
8 22.38 (16.29 – 30.76)
9 23.64 (10.62 – 52.61)
*Score 0: Patients can be administered aspirin*Score 1: Patients can be administered aspirin or anticoagulant therapy*Score ≥2: Patients should be administered anticoagulant therapy†Includes peripheral artery embolism, ischemic stroke, and pulmonary embolism
11. For patient with cardioembolic (AF) stroke/TIA which of the following Antitrhombotic Agents is recommended for secondary prevention
a. Warfarin
b. Dabigatran (Pradax)
c. Rivaroxaban (Xaralto)
d. Apixaban (Eliquis)
e. Clopidogrel + ASA
f. ASA/ER Dipyridamole
11. For patient with cardioembolic (AF) stroke/TIA which of the following Antitrhombotic Agents is recommended for secondary prevention
a. Warfarin
b. Dabigatran (Pradax)
c. Rivaroxaban (Xarelto)
d. Apixaban (Eliquis)
e. Clopidogrel + ASA
f. ASA/ER Dipyridamole
1. Haas S. J Thromb Thrombolysis. 2008;25:52-60.2. Adapted from Ezekowitz MD et al. Mayo Clin Proc. 2004;79:904-913.
Narrow efficacy window + multiple interactions
Challenges of Oral Anticoagulation Therapy (OAC)
hard to use/take1=
ISCHEMIC STROKE INTRACRANIAL BLEED
Od
ds
Rat
io
05.0 6.0 8.0
INR
1.0 2.0 3.0 4.0 7.0
5.0
15.0
10.0
1.0
20.0
INR control: clinical trials v. clinical practice
INR* control in clinical trial versus clinical practice (TTR**)
1. Kalra L, et al. BMJ 2000;320:1236-1239 * Pooled data: up to 83% to 71% in individualized trials; 2. Matchar DB, et al. Am J Med 2002; 113:42-51.
** TTR = Time in Therapeutic Range (INR2.0-3.0)
66%
44%
9%
18%
38%
25%
<2.0 2.0 – 3.0 >3.0 INR
% o
f e
ligib
le p
ati
en
ts
rec
eiv
ing
wa
rfa
rin
Clinical trial1
Clinical practice2
*INR = International normalized ratio
12. Despite the challenges of using warfarin, the lack of antidote for the NOAC makes them less valuable than warfarin in cardioembolic prophylaxis in acute stroke
True
False
12. Despite the challenges of using warfarin, the lack of antidote for the NOAC makes them less valuable than warfarin in cardioembolic prophylaxis in acute stroke
True
False
New OAC• Dabigatran Etexilate (Direct thrombin inhibitor)
in Atrial Fibrillation (RE-LY)
• Rivaroxaban (Factor Xa inhibitor)in Atrial Fibrillation (ROCKET-AF)
• Apixaban (Factor Xa inhibitor)in Atrial Fibrillation (AVERROES; ARISTOTLE)
• Dabigatran Etexilate (Direct thrombin inhibitor) in Atrial Fibrillation (RE-LY)
• Rivaroxaban (Factor Xa inhibitor)in Atrial Fibrillation (ROCKET-AF)
• Apixaban (Factor Xa inhibitor)in Atrial Fibrillation (AVERROES; ARISTOTLE)
Pros: No MonitoringRapid onset of actionSimilar or better bleeding profile to warfarin
Con: No antidote, no clear way of measuring effect
Prevention of Stroke
Connolly N Engl J Med 2010;363:1876; Patel N Engl J Med 2011;365:883; Granger N Engl J Med 2011;365:981
0.50 0.75 1.00 1.25 1.50
Dabigatran 110 mg BID
Dabigatran 150 mg BID
HR (95% CI)Warfarin betterComparator better
Rivaroxaban 20 mg QD
Apixaban 5 mg BID
Stroke or Systemic Embolism
Ischemic StrokeDabigatran 110 mg BID
Dabigatran 150 mg BID
Rivaroxaban 20 mg QD
Apixaban 5 mg BID
Superiorityp-value
0.29<0.001 0.12 0.01
0.350.03 0.59
0.42
0.90
0.65
1.11
0.76
0.88
0.79
0.94
0.92
Cross-trial comparisons must be interpreted with caution due to differing methodologies and patient populations.
Reducing the Bleeding Risk
HR (95% CI)Warfarin betterComparator better
0.50 0.75 1.00 1.250.25
Dabigatran 110 mg BID
Dabigatran 150 mg BID
Rivaroxaban 20 mg QD
Apixaban 5 mg BID
Intracranial Hemorrhage
ISTH Major BleedingDabigatran 110 mg BID
Dabigatran 150 mg BID
Rivaroxaban 20 mg QD
Apixaban 5 mg BID
Superiorityp-value
<0.001
<0.001
0.02 <0.001
0.0030.31 0.58
<0.001
Connolly N Engl J Med 2010;363:1876; Patel N Engl J Med 2011;365:883; Granger N Engl J Med 2011;365:981
0.80
0.93
0.30
0.41
0.67
0.42
1.04
0.69
Cross-trial comparisons must be interpreted with caution due to differing methodologies and patient populations.
AF Trials: Elements of Primary Endpoint:*Annual Event Rates
Connolly N Engl J Med 2010;363:1876; Patel N Engl J Med 2011;365:883; Granger N Engl J Med 2011;365:981
In recent trials, the majority of AF strokes were ischemic
Cross-trial comparisons must be interpreted with caution due to differing methodologies and patient populations.
†
*Patients experiencing multiple endpoints are included in multiple categories.†Systemic embolism result reported for RELY refers to pulmonary embolism.
CCS 2012 Update to AF Guidelines
When oral anticoagulant therapy is indicated, most patients should receive dabigatran, rivaroxaban, or apixaban, in
preference to warfarin
• Dabigatran and apixaban have greater efficacy and rivaroxaban has similar efficacy for stroke prevention
• Dabigatran and rivaroxaban have no more major bleeding and apixaban has less
• All three new oral anticoagulants have less intracranial hemorrhage and are much simpler to use
1. Skanes AC, et al. Can J Cardiol 2012;28:125-136.
Poor Prognosis in Warfarin-Associated Intracranial Hemorrhage
Despite Anticoagulant Reversal
Dowlatshahi D, et al. Stroke 2012. DOI: 10.1161/STROKEAHA.112.652065
Hematoma Growth
Significant hematoma growth despite INR correction with PCC.
This patient was treated with 1000 U of PCC and 10 mg vitamin K 98 minutes after baseline CT scan.
Repeat INR was 1.3, 42 minutes after PCC treatment and 1.2 the next day.
INR = international normalized ratio;
PCC = prothrombin complex concentrate
Dowlatshahi D, et al. 2012. DOI: 10.1161/STROKEAHA.112.652065
Poor Outcomes
Intracranial hemorrhage type Number In-hospital mortality*
Discharge mRS(Median IQR)†
Intraparenchymal 71 30 (42.3%) 5 (3)‡
Subdural 61 21 (34.4%) 3 (4)§
Epidural 1 0 3
Subarachnoid 8 1 (12.5%) 3 (3)
ICH = intracranial hemorrhage; mRS = modified Rankin Scale; IQR = interquartile range
*P = 0.3; †P=0.012; ‡mRS missing in 9; §mRS missing in 2
Outcome by anticoagulant-associated ICH
Dowlatshahi D, et al. 2012. DOI: 10.1161/STROKEAHA.112.652065
30 Day Mortality Associated with Intracranial vs Extracranial Bleeds
• Data from The AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study- a cohort of 13,559 adults with diagnosed nonvalvular atrial fibrillation who received care within Kaiser Permanente of Northern California, a large integrated
• health care delivery system. Risk of death 30 days after hospitalization for warfarin-associated intracranial hemorrhage versus major extracranial hemorrhage; 95% confidence intervals (CIs) (vertical bars). P value refers to the chi-square comparison of mortality rate of intracranial versus extracranial hemorrhage.
Fang et al, The American Journal of Medicine (2007) 120, 700-705
Intracranial Extracranial0
20
40
60
80
100
48.6
5.1
IntracranialExtracranial
Mo
rta
lity
at 3
0 d
ays
(%
)
P<0.001
• Prothrombin complex concentrates (PCC) therapy rapidly corrected INR in the majority of patients with anticoagulant-associated ICH, yet mortality and morbidity rates remained high
• Outcomes after anticoagulant-associated ICH can be devastating even with a reversal strategy
Conclusion
Dowlatshahi D, et al. 2012. DOI: 10.1161/STROKEAHA.112.652065
12. Despite the challenges of using warfarin, the lack of antidote for the NOAC makes them less valuable than warfarin in cardioembolic prophylaxis in acute stroke